BioArctic's Q2 Report: Follow the 9% Royalty on Leqembi, Not the Headline Profit

If you read only the headline number in BioArctic's April–June report, published on August 26, you would see a company stumbling: net revenue down 37% from a year earlier, the operating line swinging from a profit to a SEK 6.5 million loss, and the stock sliding about 8% to roughly SEK 317 on the day.

The quarterly profit line is the wrong place to look with this company. BioArctic does not sell Leqembi, the Alzheimer's drug it is best known for. Eisai sells it. BioArctic collects a royalty of 9 percent on Leqembi's global sales under its alliance with Eisai, plus milestone payments on top. That royalty is not a side business — it is effectively the whole business. The stock is a leveraged claim on one number: Leqembi's quarterly sales, and the slope of that curve.

The one number that compounds

Put that royalty in motion. Second-quarter royalty income was SEK 179.4 million, up 10% as reported — but a year earlier Leqembi's Chinese launch had briefly produced a stockpiling effect worth around ¥5.3 billion, and stripping that out, BioArctic's own release put Q2 royalty growth at about 43%. The first quarter of 2026 had already grown 68% year over year. For the first half as a whole, royalties came to roughly SEK 340 million, about a third higher than the year-earlier period on a reported basis.

Then there is the forward number, and it is the big one. Eisai's forecast for its fiscal year (April 2026 through March 2027) calls for Leqembi sales of ¥143.5 billion — around SEK 8.4 billion — which would be 63% growth and maps to roughly SEK 880 million of royalty income for BioArctic. The drug is approved in 53 countries, with six more under regulatory review.

Why the income statement says something different

So why did revenue fall and the operating line lose money if royalties rose? Because revenue is not just royalties. A year ago, the second quarter carried a milestone payment of €20 million tied to Leqembi's European approval — roughly SEK 230 million in round numbers. This year's quarter had no such boost, leaving net revenue of SEK 247.5 million that was mostly the SEK 179.4 million of royalties plus a smaller non-royalty amount. Meanwhile, BioArctic is deliberately spending more: it has guided operating costs up 40–60% for 2026 as R&D expands.

The company-level income statement is a leftover — high-margin royalty income minus fast-rising R&D spend, with milestone timing swinging individual quarters. Q1 2026 carried a €20 million sales milestone (triggered once Leqembi's cumulative sales passed €500 million) and the operating line showed a SEK 210.8 million profit; Q2 had no milestone and showed minus SEK 6.5 million. None of that tells you whether the investment case is intact. The royalty trajectory does.

The checkpoint behind the 63% number

Here is the concrete test the forecast requires. Leqembi's first fiscal quarter (April–June) delivered ¥29.3 billion in sales. For Eisai's full-year target to be met, the remaining three quarters must average about ¥38 billion each — a jump of roughly 30% in the quarterly run-rate from today's level, and well above the year-earlier pace for those same months.

The catalysts are lined up. On August 24, BioArctic and Eisai launched Leqembi Iqlik in the US — the subcutaneous autoinjector that lets patients do weekly at-home dosing from the very first infusion rather than reporting to a clinic. Japan is expected to decide on starting patients with the autoinjector in the third quarter, and China has the subcutaneous version under priority review after Leqembi's addition to a commercial-insurance innovative-drug list in late 2025. The next Leqembi sales announcement, alongside Eisai's numbers in late October, is the first real test of whether that step-up is happening.

What the price already assumes

Now the valuation arithmetic, on stated assumptions. With about 88.7 million shares and the price near SEK 317, the market cap comes to roughly SEK 28 billion, or about $2.7 billion. Against this year's expected royalty income of around SEK 880 million, that is about 30 times — a multiple that only holds up if the royalty keeps compounding at high rates for years.

Run the implied math the other way. Suppose a buyer would pay a generous 20 times for a rapidly growing royalty stream. To cover SEK 28 billion at 20 times, royalties would need to be about SEK 1.4 billion; at a 9% take, that requires Leqembi sales of roughly SEK 15.5 billion, about 85% above the current annual forecast of SEK 8.4 billion. Demand a more conservative 15 times and the implied requirement is roughly two and a half times today's forecast. In plain terms: the price already assumes Leqembi grows from around $0.9 billion of annual sales toward $1.5–2 billion, before the pipeline counts for anything.

There is, of course, something else. Lilly signed on in June for BioArctic's BrainTransporter brain-delivery technology — a $30 million upfront, up to $770 million in milestones, plus tiered royalties. Novartis made a similar $30 million bet in 2025, and Bristol Myers Squibb paid a $100 million upfront in early 2025 for two Alzheimer's antibodies. These deals validate the platform and throw off lumpy cash, but lumpy is the operative word: upfront and milestone money does not compound the way a royalty does, and it is not a recurring base a multiple should be built on.

Where the disagreement lives

The comparative read points the same direction. The market broadly likes Leqembi exposure: Biogen, which co-sells the drug in the US, trades near a 52-week high, up about 25% year to date. The fight is inside BioArctic's own valuation. Published targets this year have ranged from DNB's Buy at SEK 363 and Handelsbanken's Buy at SEK 355, through Goldman's neutral SEK 339, down to Nordea's Sell at SEK 240. Same company, same data. That spread is not a disagreement about credibility — it is a disagreement about how steeply Leqembi's curve bends from here.

Portfolio role, and the trigger that changes the call

Where does that leave a position? BioArctic is a high-beta growth satellite, not a portfolio anchor. It carries two concentrations a disciplined account sizes against: essentially one commercial product, and one commercial partner, since Eisai controls launch, pricing, and promotion. Approval does not equal adoption: Sweden's own NT Council currently does not recommend introducing Leqembi in its healthcare system, a reminder that reimbursement is a separate fight from registration. The balance sheet is the comfort — about SEK 2.0 billion in cash and short-term investments at the end of June, and a board-proposed dividend of SEK 2.00 for 2025, small but newly started.

On the factor read the disclosed numbers support — growth strong and re-accelerating, profitability a royalty-line story rather than a company-margin story, safety clean, momentum negative on the day but below the year's earlier peak — the trigger that changes the verdict is the same in every frame: the quarterly Leqembi sales print. If the run-rate climbs toward that ¥38 billion average, the ~30 times on this year's royalties compounds down quickly and the Buy camp earns its targets. If the autoinjector ramp stalls and China and Japan drag, the SEK 240 case gains the argument.

Watch the sales number, not the quarter's profit line. BioArctic's shares are Leqembi's sales volume with operating leverage on top, and the next chapter is written one quarterly sales announcement at a time.